CytoSorbents Announces $6.25 Million Common Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility

$4.0 million registered direct offering of common stock, led by existing shareholders and management $2.25 million of Avenue debt satisfied through the issuance of common stock at the same offering price Total debt reduced by $5.25 million, to $12.25 million, saving approximately $0.7 million in interest over 12 months Maturity extended one year to July […]

November 20, 2026